Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Biol Blood Marrow Transplant. 2011 Apr;17(4):465-75. doi: 10.1016/j.bbmt.2010.04.016. Epub 2010 May 10.
Stable mixed hematopoietic chimerism has been consistently established in dogs who were mildly immunosuppressed by 200 cGy of total body irradiation (TBI) before undergoing dog leukocyte antigen (DLA)-identical bone marrow (BM) transplantation and who received a brief course of immunosuppression with mycophenolate mofetil (28 days) and cyclosporine (35 days) after transplantation. However, when TBI was reduced from 200 to 100 cGy, grafts were nearly uniformly rejected within 3-12 weeks. Here, we asked whether stable engraftment could be accomplished after a suboptimal dose of 100 cGy TBI with host immunosuppression enhanced by donor-derived mesenchymal stromal cells (MSCs) given after transplantation. MSCs were cultured from BM cells and evaluated in vitro for antigen expression. They showed profound immunosuppressive properties in mixed lymphocyte reactions (MLRs) in a cell dose-dependent manner not restricted by DLA. MSC and lymphocyte contact was not required, indicating that immunosuppression was mediated by soluble factors. Prostaglandin E2 was increased in culture supernatant when MSCs were cocultured in MLRs. The addition of indomethacin restored lymphocyte proliferation in cultures containing MSCs. MSCs expressed CD10, CD13, CD29, CD44, CD73/SH-3, CD90/Thy-1, and CD106/VCAM-1. For in vivo studies, MSCs were injected on the day of BM grafting and on day 35, the day of discontinuation of posttransplantation cyclosporine. MSCs derived from the respective BM donors failed to avert BM graft rejection in 4 dogs who received DLA-identical grafts after nonmyeloablative conditioning with 100 cGy TBI in a time course not significantly different from that of control dogs not given MSCs. Although the MSCs displayed in vitro characteristics similar to those reported for MSCs from other species, their immunosuppressive qualities failed to sustain stable BM engraftment in vivo in this canine model.
稳定的混合造血嵌合体已在接受狗白细胞抗原(DLA)匹配骨髓(BM)移植前接受 200cGy 全身照射(TBI)轻度免疫抑制的狗中建立,这些狗在移植后接受霉酚酸酯(28 天)和环孢素(35 天)的短暂免疫抑制治疗。然而,当 TBI 从 200 减少到 100cGy 时,移植物在 3-12 周内几乎全部被排斥。在这里,我们询问在接受移植后给予供体来源的间充质基质细胞(MSCs)增强宿主免疫抑制的情况下,100cGyTBI 的亚最佳剂量是否可以实现稳定的植入。从 BM 细胞中培养 MSCs 并在体外进行抗原表达评估。它们在混合淋巴细胞反应(MLR)中表现出强烈的免疫抑制特性,这种特性呈细胞剂量依赖性,不受 DLA 限制。MSCs 和淋巴细胞之间不需要接触,表明免疫抑制是由可溶性因子介导的。当 MSCs 在 MLR 中共培养时,培养上清液中前列腺素 E2 增加。在含有 MSCs 的培养物中加入吲哚美辛可恢复淋巴细胞增殖。MSCs 表达 CD10、CD13、CD29、CD44、CD73/SH-3、CD90/Thy-1 和 CD106/VCAM-1。对于体内研究,在 BM 移植物移植当天和移植后环孢素停用的第 35 天注射 MSCs。在非清髓性条件下接受 100cGyTBI 和 DLA 匹配移植物的 4 只狗中,来自各自 BM 供体的 MSCs 未能避免 BM 移植物排斥,其时间过程与未给予 MSCs 的对照狗没有显著差异。尽管这些 MSCs 在体外表现出与其他物种的 MSCs 相似的特征,但它们的免疫抑制特性未能在该犬模型中维持体内 BM 植入的稳定。